FDA Approves Yartemlea, the First and Only Treatment for Transplant-Related Blood Vessel Damage

Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children ages 2 years or older. TA-TMA is a serious… Read more

Aqvesme: FDA Approves First Pill for Treating Anemia in Adults With Alpha- or Beta- Thalassemia

Aqvesme (mitapivat) is a new oral medicine approved by the FDA for treating anemia in adults with alpha- or beta-thalassemia, including those who need and those who don’t require regular blood transfusions. Thalassemia is a… Read more

Nereus: FDA Approves New Pill to Help With Motion Sickness

Nereus (tradipitant) is a new prescription medicine approved by the FDA to help prevent nausea and vomiting caused by motion (motion sickness) in adults, such as during car rides, boat trips, or flights. Motion sickness… Read more

Hernexeos: FDA Approves First-Line Use for Certain Advanced Non-Small-Cell Lung Cancers With HER2 Mutations

Hernexeos (zongertinib) is a prescription medicine known as a kinase inhibitor that is used for treating adults with advanced non-small-cell lung cancer (NSCLC) that cannot be removed surgically or has spread to other parts of… Read more

Keytruda With Paclitaxel: FDA Approves New Combination Therapy for Certain Cancers Affecting the Ovaries, Fallopian Tubes, or Peritoneum

The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum). This treatment is meant for patients whose cancers express… Read more

FDA Approves Rybrevant Faspro: A Time-Saving Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer

Rybrevant Faspro is a new under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called Lazcluze (lazertinib) as a first-line treatment for… Read more

Adquey: FDA Approves New Nonsteroidal Ointment for Mild to Moderate Eczema

Adquey (difamilast 1%) is a prescription ointment the FDA has approved for adults and for children 2 and older who have mild to moderate atopic dermatitis (AD), often called eczema. It is a nonsteroidal medicine… Read more

Yuvezzi: First Combination Eye Drop for Age-Related Near Vision Loss

Yuvezzi is a new prescription eye drop approved to treat presbyopia, a common condition that makes it harder to see things up close as you age. It’s the only FDA-approved eye drop that combines two… Read more

Rybrevant Faspro: FDA Approves Once-Monthly Dosing in Combination With Lazcluze for EGFR-Mutated Lung Cancer

Rybrevant Faspro is an under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has approved a new monthly dosing option for Rybrevant Faspro to be used in combination with the oral… Read more

FDA Approves Cablivi: New Treatment Option for Rare Blood Clotting Disorder in Children Ages 12 Years and Older

Cablivi (caplacizumab) is an injectable medicine used to treat a rare and serious blood condition called acquired thrombotic thrombocytopenic purpura (aTTP). The FDA has approved Cablivi to be used along with plasma exchange and immunosuppressive… Read more